Previous 10 | Next 10 |
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement PR Newswire ROCKVILLE, Md. , July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx") , a clinical-stage drug development company focused on tissue prot...
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement PR Newswire ROCKVILLE, Md. , June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue p...
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome Pooled Data from Three Phase 3 Clinical Trials in ~1500 Patients Shows Statistically Significant Improvements of Signs and Symptoms of DES PR Newswire ...
RegeneRx Biopharmaceuticals ([[RGRX]] +8.7%) expects to finish all the data analysis from its ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome by April, with preparation and submission of Pre-BLA meeting request by the end of August.The top...
RegeneRx Issues Update on ARISE-3 Trial PR Newswire ROCKVILLE, Md. , March 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regenerati...
RegeneRx Biopharmaceuticals (RGRX) announces that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of dry eye syndrome did not meet its primary outcome measures.However, the company highlighted that efficacy was seen in the improvement of ocular grittiness, one...
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial PR Newswire ROCKVILLE, Md. , March 18, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tiss...
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial PR Newswire ROCKVILLE, Md. , Feb. 24, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on...
OTC listed RegeneRx Biopharmaceuticals ([[RGRX]] -12.9%) is addressing rumors in the market regarding its ARISE-3 phase 3 trial evaluating RGN-259 in dry eye.The company said that based on communication with its partner, GtreeBNT, the patient database in the 700-subject trial, ...
RegeneRx Comments on ARISE-3 Clinical Trial PR Newswire ROCKVILLE, Md. , Jan. 26, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protectio...
News, Short Squeeze, Breakout and More Instantly...
Regenerx Biopharms Inc Company Name:
RGRX Stock Symbol:
OTCMKTS Market:
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development company focused o...
RegeneRx To Extend Consent Solicitation Vote PR Newswire ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and...